Canada Electroretinography Market Size & Outlook, 2026-2034
Canada Electroretinography Market Insights
- Reed Intelligence analysis indicates that the Canada Electroretinography Market size, valued at USD 68.32 Million in 2025, is expected to expand to USD 135.16 Million by 2034.
- The Canada market is forecasted to expand at a CAGR of 7.95% spanning 2026–2034.
- Full-field ERG held the leading position among Type segments in 2025, based on market size.
- Pattern ERG is projected to post the fastest growth rate, sustaining its position as the most attractive Type segment during the forecast horizon.
![Canada Electroretinography Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/canada-electroretinography-market-canada-type-103681.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Canada accounted for 10.68% of the global Electroretinography Market size.
- By 2034, United States is expected to lead the global Electroretinography Market in terms of market size.
- Within North America, United States is projected to dominate the regional Electroretinography Market size by 2034.
- Canada is identified as the fastest-growing market in North America, anticipated to reach USD 136 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 68.32 Million |
| Market Size In 2034 | USD 135.16 Million |
| Largest segment | Full-field ERG |
| Units | Revenue in USD Million |
| CAGR | 7.95% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Product Type |
|
| Application |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Canada Electroretinography Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Full-field ERG | XX.x | XX.x | XX.x | 33.15 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Multifocal ERG | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pattern ERG | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Portable ERG | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Canada Electroretinography Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equipment | XX.x | XX.x | XX.x | 35.98 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Electrodes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Accessories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Canada Electroretinography Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | XX.x | XX.x | XX.x | 37.7 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Canada Electroretinography Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 31.27 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.